Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun;65(4):e92-e96.
doi: 10.1111/ajd.14213. Epub 2024 Jan 24.

Real-life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study

Caldarola Giacomo  1   2 , Trovato Emanuele  3 , Burlando Martina  4   5 , Capalbo Eugenio  3 , Diotallevi Federico  6 , Lora Viviana  7 , Pinto Lorenzo Maria  1   2 , Gaeta Shumak Ruslana  8 , Fastame Maria Thais  9 , Mariani Marco  10 , Campione Elena  8 , Offidani Annamaria  6 , Parodi Aurora  4   5 , Prignano Francesca  9
Affiliations
Multicenter Study

Real-life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study

Caldarola Giacomo et al. Australas J Dermatol. 2024 Jun.

Abstract

Palmoplantar (PP) psoriasis is considered one of the most hard-to-treat areas with important impact on patients' quality of life, and few data are available about the efficacy of dimethylfumarate (DMF) on these areas. In our noninterventional multicentre retrospective cohort study of patients with PP psoriasis treated with DMF, effectiveness was evaluated as mean pp Psoriasis Area and Severity Index (ppPASI) reduction and as proportion of patients that reach ppPASI 75 at 4, 12, 24 and 48 weeks. The reduction in ppPASI was 23.5% at w4, 49.7% at w12, 69.1% at w24 and 81.1% at w48. pp Investigator's Global Assessment (ppIGA) 0/1 was reached by 5 patients (10.64%) at w4, 10 patients (23.8%) at w12, 11 patients (40.7%) at w24 and 12 patients (60%) at w48 confirming that DMF could represent an effective therapy in patients affected by PP psoriasis. Overall, the treatment was well tolerated although only 24 patients made it to 24 weeks of therapy and 28 patients completed the observation period at 48 weeks. None of the patients reported adverse events requiring discontinuation of the drug. However, this discontinuation rate is in line with clinical trials and real-world evidence.

Keywords: dimethylfumarate; efficacy; palms; psoriasis; soles.

PubMed Disclaimer

References

REFERENCES

    1. Mrowietz U, Barker J, Boehncke WH, Iversen L, Kirby B, Naldi L, et al. Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32(Suppl 3):3–14.
    1. Norlin JM, Calara PS, Persson U, Schmitt‐Egenolf M. Real‐world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy. J Dermatolog Treat. 2017;28(6):500–504.
    1. Augustin M, Landeck L, Diemert S, Asadullah K, Hammann U, Ertner K, et al. Long‐term treatment with dimethyl fumarate for plaque psoriasis in routine practice: good overall effectiveness and positive effect on impactful areas. Dermatol Ther (Heidelb). 2022;12(5):1121–1131.
    1. Esposito M, Campanati A, Giunta A, Calianno G, Bianchi L, Diotallevi F, et al. Dimethyl Fumarate's effectiveness and safety in psoriasis: a real‐life experience during the COVID‐19 pandemic. Dermatol Ther (Heidelb). 2022;12(3):671–681.
    1. Kt S, Thakur V, Narang T, et al. Comparison of the efficacy and safety of Apremilast and methotrexate in patients with palmoplantar psoriasis: a randomized controlled trial. Am J Clin Dermatol. 2021;22(3):415–423.

Publication types

LinkOut - more resources